Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Galena Biopharma, Inc. (SLS) had Return on Tangible Equity of -22.49% for the most recently reported fiscal quarter, ending 2025-03-31.
| Income Statement Financials | |
-- |
|
$-5.81M |
|
-- |
|
-- |
|
$6.06M |
|
$-6.06M |
|
$0.25M |
|
$-5.81M |
|
$-5.81M |
|
$-5.81M |
|
$-5.81M |
|
$-5.81M |
|
$-5.81M |
|
$-6.06M |
|
$-6.06M |
|
87.76M |
|
87.76M |
|
$-0.07 |
|
$-0.07 |
|
| Balance Sheet Financials | |
$31.97M |
|
-- |
|
$2.98M |
|
$34.96M |
|
$6.89M |
|
-- |
|
$0.31M |
|
$7.20M |
|
$27.76M |
|
$25.84M |
|
$27.76M |
|
90.90M |
|
| Cash Flow Statement Financials | |
$-9.07M |
|
-- |
|
$23.58M |
|
$13.99M |
|
$28.50M |
|
$14.51M |
|
$0.51M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
4.64 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-9.07M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-20.94% |
|
|
Return on Tangible Equity |
-22.49% |
-16.63% |
|
-20.94% |
|
$0.31 |
|
$-0.10 |
|
$-0.10 |
|